Related references
Note: Only part of the references are listed.Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Scott E. Eggener et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Edouard J. Trabulsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline
Philip J. Saylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer
Y. Yang et al.
CURRENT ONCOLOGY (2019)
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
F. Hall et al.
QUALITY OF LIFE RESEARCH (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer
Alex P. Hoyle et al.
EUROPEAN UROLOGY (2019)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. W. Clarke et al.
ANNALS OF ONCOLOGY (2019)
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review
Thomas Van den Broeck et al.
EUROPEAN UROLOGY (2019)
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer Who Underwent Orchiectomy: A Systematic Review and Meta-analysis
Muhammed Rashid et al.
CURRENT CLINICAL PHARMACOLOGY (2019)
Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform
Duncan C. Gilbert et al.
BJU INTERNATIONAL (2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2018)
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Michael J. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
Russell Z. Szmulewitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
Cy A. Stein et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching
Mizuki Onozawa et al.
CANCER MEDICINE (2018)
Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study
F. Casas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
Timothy Gilligan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer
Seo Hyon Baik et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
Betty R. Ferrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
Huei-Ting Tsai et al.
JOURNAL OF UROLOGY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
K. T. Nead et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis
Kevin T. Nead et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
Ruth E. Langley et al.
EUROPEAN UROLOGY (2016)
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
Silke Gillessen et al.
EUROPEAN UROLOGY (2016)
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
Claude Schulman et al.
EUROPEAN UROLOGY (2016)
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M. Duchesne et al.
LANCET ONCOLOGY (2016)
Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies
Lucie-Marie Scailteux et al.
MEDICINE (2016)
A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
C. Jin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis
ZhiLong Dong et al.
AGING MALE (2015)
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Cecilia Bosco et al.
EUROPEAN UROLOGY (2015)
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
Matthew J. Resnick et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Non-inferiority trials: why oncologists must remain wary
Mauricio Burotto et al.
LANCET ONCOLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer A Systematic Review and Meta-analysis
Sindy Magnan et al.
JAMA ONCOLOGY (2015)
American Cancer Society Prostate Cancer Survivorship Care Guidelines
Ted A. Skolarus et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group
Fernando Calais da Silva et al.
EUROPEAN UROLOGY (2014)
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
Gerhardt Attard et al.
EUROPEAN UROLOGY (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis
D. Brungs et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial
Paul C. M. S. Verhagen et al.
WORLD JOURNAL OF UROLOGY (2014)
A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a perpetual dispute
Zisis Kratiras et al.
INTERNATIONAL BRAZ J UROL (2014)
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
Tobias Engel Ayer Botrel et al.
BMC UROLOGY (2014)
Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII
Arto J. Salonen et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2014)
Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa) Results of a Multi-institutional Randomized Prospective Clinical Trial
Michael Organ et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Intermittent Androgen-deprivation Therapy in Prostate Cancer: A Critical Review Focused on Phase 3 Trials
Alessandro Sciarra et al.
EUROPEAN UROLOGY (2013)
Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects
Arto J. Salonen et al.
EUROPEAN UROLOGY (2013)
Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials
Saroj Niraula et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
Ruth E. Langley et al.
LANCET ONCOLOGY (2013)
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
Johan F. Langenhuijsen et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis
Huei-Ting Tsai et al.
UROLOGY (2013)
Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial
Nicolas Mottet et al.
BJU INTERNATIONAL (2012)
Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
Richard N. Shiffman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2012)
The FinnProstate Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
Arto J. Salonen et al.
JOURNAL OF UROLOGY (2012)
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Juanita M. Crook et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy
U. W. Tunn et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2012)
Neoadjuvant androgen deprivation for prostate volume reduction: The optimal duration in prostate cancer radiotherapy
Johan F. Langenhuijsen et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Sonya Blesser Streeter et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre
Xue-Qin Chen et al.
ASIAN JOURNAL OF ANDROLOGY (2010)
Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review
Paul C. M. S. Verhagen et al.
EUROPEAN UROLOGY (2010)
Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival
Hideyuki Akaza et al.
CANCER (2009)
Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)
Fritz H. Schroder et al.
EUROPEAN UROLOGY (2009)
Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
Fernando E. C. Calais da Silva et al.
EUROPEAN UROLOGY (2009)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Continuous versus six months a year maximal androgen blockade in the management of prostate cancer:: A randomised study
Jacques Irani et al.
EUROPEAN UROLOGY (2008)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intermittent versus continuous androgen suppression in advanced prostate cancer - A randomised prospective study
Kurt Miller et al.
JOURNAL OF UROLOGY (2007)
Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer
H Yamanaka et al.
PROSTATE (2005)
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor:: Results of European Organisation for the Research and Treatment of Cancer 30846 -: A phase III study
FH Schröder et al.
JOURNAL OF UROLOGY (2004)
Timing and choice of androgen ablation
D Kirk
PROSTATE CANCER AND PROSTATIC DISEASES (2004)
American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer
DA Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88
UE Studer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
